MASCT-I + gemcitabine + carboplatin

MASCT-I + gemcitabine + carboplatin is a combination regimen consisting of Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) with the chemotherapeutic agents gemcitabine and carboplatin. MASCT-I is an immunotherapy where autologous dendritic cells are induced from a patient's peripheral blood, loaded with tumor antigens, and re-infused to stimulate specific cytotoxic T-cell responses against multiple antigens[1][3]. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis in rapidly dividing cells. The combination is under investigation for advanced and metastatic solid tumors, including metastatic urothelial carcinoma[3][1].